Personalizing HER2-Targeted Therapy in Metastatic Breast Cancer Beyond HER2 Status: What We Have Learned from Clinical Specimens

Publisher： Bentham Science Publishers

E-ISSN： 1875-6913|7|4|263-274

ISSN： 1875-6921

Source： Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol.7, Iss.4, 2009-12, pp. : 263-274

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Beyond Trastuzumab: Overcoming Resistance to Targeted HER-2 Therapy in Breast Cancer

By  

Current Cancer Drug Targets, Vol. 9, Iss. 2, 2009-03 ,pp. : 148-162

Bentham Science Publishers

Access to resources Recommend Favorite

HER-2-positive metastatic breast cancer: trastuzumab and beyond

By Metro Giulio   Mottolese Marcella   Fabi Alessandra  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 15, 2008-10 ,pp. : 2583-2601

Informa Healthcare

Access to resources Recommend Favorite

Novel Targeted Therapies to Overcome Trastuzumab Resistance in HER2- Overexpressing Metastatic Breast Cancer

By  

Current Drug Targets, Vol. 14, Iss. 8, 2013-07 ,pp. : 889-898

Bentham Science Publishers

Access to resources Recommend Favorite

Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer

By Gullo Giuseppe   Bettio Daniela   Torri Valter   Masci Giovanna   Salvini Piermario   Santoro Armando  

Investigational New Drugs, Vol. 27, Iss. 2, 2009-04 ,pp. : 179-183

Springer Publishing Company

Access to resources Recommend Favorite

Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature

By Arslan Cagatay   Sari Ebru   Aksoy Sercan   Altundag Kadri  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 1, 2011-01 ,pp. : 21-30

Informa Healthcare

Access to resources Recommend Favorite